AJNR Am J Neuroradiol
- ZHANG HQ, Lee JC, Wang L, Cao P, et al
Dynamic Changes in Long-Standing Multiple Sclerosis Revealed by Longitudinal
Structural Network Analysis Using Diffusion Tensor Imaging.
AJNR Am J Neuroradiol. 2024 Feb 1. doi: 10.3174/ajnr.A8115.
Arch Phys Med Rehabil
- SILVEIRA SL, Motl RW, Salter A, Marquez DX, et al
Social cognitive theory variables as correlates of physical activity behavior
among Hispanics with multiple sclerosis.
Arch Phys Med Rehabil. 2024 Jan 26:S0003-9993(24)00053.
BMC Neurol
- LE HH, Ken-Opurum J, LaPrade A, Maculaitis MC, et al
Exploring humanistic burden of fatigue in adults with multiple sclerosis: an
analysis of US National Health and Wellness Survey data.
BMC Neurol. 2024;24:51.
Brain
- HERRANZ E, Treaba CA, Barletta VT, Mehndiratta A, et al
Characterization of cortico-meningeal translocator protein expression in multiple
sclerosis.
Brain. 2024 Jan 30:awae030. doi: 10.1093.
J Neurol
- BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
Ocrelizumab reduces cortical and deep grey matter loss compared to the
S1P-receptor modulator in multiple sclerosis.
J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
- BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI
patterns and its development over time.
J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
- NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
Neurophysiological brain function predicts response to cognitive rehabilitation
and mindfulness in multiple sclerosis: a randomized trial.
J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
- BISECCO A, Matrone F, Capobianco M, De Luca G, et al
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing
of ocrelizumab in MS patients.
J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
- RIVEL M, Achiron A, Stern Y, Zeilig G, et al
Emotional burden among MS patients: associations between specific chronic pain
diagnoses and psychological features.
J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
J Neurol Sci
- HJAERESEN S, Benedikz E, Sejbaek T, Axelsson M, et al
High temperature requirement A1 and macrophage migration inhibitory factor in the
cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to
secondary progressive multiple sclerosis.
J Neurol Sci. 2024;457:122888.
- ZANETTA C, Faustino P, Guerrieri S, Nozzolillo A, et al
Fast but not furious: Rapid ocrelizumab infusion as a strategy to optimize
multiple sclerosis patients' management.
J Neurol Sci. 2024;457:122897.
Mult Scler
- NAKAMURA K, Thoomukuntla B, Bena J, Cohen JA, et al
Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
Mult Scler. 2024 Jan 29:13524585231224702. doi: 10.1177/13524585231224702.
- SWITAL M, Drouin J, Miranda S, Bakchine S, et al
Use of multiple sclerosis disease-modifying therapies during pregnancy in France:
Nationwide study between 2010 and 2021.
Mult Scler. 2024 Jan 27:13524585231223395. doi: 10.1177/13524585231223395.
- MISCIOSCIA A, Treaba CA, Barletta VT, Herranz E, et al
White matter paramagnetic rim and non-rim lesions share a periventricular
gradient in multiple sclerosis: A 7-T imaging study.
Mult Scler. 2024 Jan 27:13524585231224681. doi: 10.1177/13524585231224681.
Neurology
- BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With
Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
Neurology. 2024;102:e208059.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016